Eagle Pharmaceuticals, Inc. (EGRX) Financial Statements (2024 and earlier)

Company Profile

Business Address 50 TICE BOULEVARD, SUITE 315
WOODCLIFF LAKE, NJ 07677
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments21,89755,32115,38442,77275,497 
Cash and cash equivalents21,89755,32115,38436,56269,522 
Short-term investments    6,2105,975 
Receivables114,95372,43996,93285,920130,858 
Inventory, net of allowances, customer advances and progress billings44,14047,79463,85557,71224,818 
Inventory44,14047,79463,85557,71224,818 
Prepaid expense1,9673481,1031,6801,166 
Other current assets2,5753,2592,1652,9034,762 
Other undisclosed current assets6,9599,5935,6073,4693,065 
Total current assets:192,491188,754185,046194,456240,166 
Noncurrent Assets
Property, plant and equipment1,1161,1681,2971,4591,627 
Intangible assets, net (including goodwill)157,908163,360150,579155,53149,683 
Goodwill45,03345,03341,79443,05739,743 
Intangible assets, net (excluding goodwill)112,875118,327108,785112,4749,940 
Deferred income tax assets29,15027,14623,54123,24421,231 
Other noncurrent assets33,51025,73225,9867,0667,458 
Total noncurrent assets:221,684217,406201,403187,30079,999 
TOTAL ASSETS:414,175406,160386,449381,756320,165 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities90,309104,83796,319100,16677,917 
Taxes payable5,75010,270 
Employee-related liabilities3,7022,775 
Accounts payable17,10818,99313,21519,97114,509 
Accrued liabilities73,20185,84473,65267,15063,408 
Debt7,5006,25034,96121,84323,725 
Other undisclosed current liabilities  (9,452)(13,045)  
Total current liabilities:97,809111,087121,828108,964101,642 
Noncurrent Liabilities
Long-term debt and lease obligation68,82956,21626,43128,018  
Long-term debt, excluding current maturities68,82956,21626,43128,018  
Liabilities, other than long-term debt4,6925,2976,4106,7922,563 
Deferred income tax liabilities   4,5364,536  
Other liabilities4,6925,2971,8742,2562,563 
Total noncurrent liabilities:73,52161,51332,84134,8102,563 
Total liabilities:171,330172,600154,669143,774104,205 
Equity
Equity, attributable to parent242,845233,560231,780237,982215,960 
Common stock1818181817 
Treasury stock, value(243,115)(243,115)(243,115)(233,164)(233,164) 
Additional paid in capital369,800366,265362,161358,377328,769 
Accumulated other comprehensive income (loss)(1,112)(1,112)9,3772,281418 
Retained earnings117,254111,504103,339110,470119,920 
Total equity:242,845233,560231,780237,982215,960 
TOTAL LIABILITIES AND EQUITY:414,175406,160386,449381,756320,165 

Income Statement (P&L) ($ in thousands)

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
Revenues66,30560,69965,90174,136115,874(129,226)
Cost of revenue
(Cost of Goods and Services Sold)
(17,300)(18,242)(20,869)(21,171)(25,176) 
Gross profit:49,00542,45745,03252,96590,698 
Operating expenses(37,232)(32,991)(35,570)(50,762)(30,869) 
Operating income:11,7739,4669,4622,20359,829 
Nonoperating income (expense)(1,542)3,838(13,125)(8,071)(2,169) 
Investment income, nonoperating212317(444)244154 
Other nonoperating income (expense)(238)5,501(11,534)(7,763)(1,957) 
Interest and debt expense(1,516) (1,147)(552)(366) 
Income (loss) from continuing operations before equity method investments, income taxes:8,71513,304(4,810)(6,420)57,294 
Other undisclosed income from continuing operations before income taxes1,516 1,147552366 
Income (loss) from continuing operations before income taxes:10,23113,304(3,663)(5,868)57,660 
Income tax expense(4,481)(5,139)(3,468)(3,582)(13,602) 
Income (loss) from continuing operations:5,7508,165(7,131)(9,450)44,058 
Income (loss) before gain (loss) on sale of properties:(7,131)(9,450)44,058
Net income (loss) available to common stockholders, diluted:5,7508,165(7,131)(9,450)44,058 

Comprehensive Income ($ in thousands)

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
Net income (loss):5,7508,165(7,131)(9,450)44,058 
Comprehensive income (loss):5,7508,165(7,131)(9,450)44,058 
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  (10,489)7,0961,863512 
Comprehensive income (loss), net of tax, attributable to parent:5,750(2,324)(35)(7,587)44,570 

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: